Phaseline

Targets › HLA-A2

HLA-A2: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Gastroenterology; next expected readout Sep 2040.

Open in Phaseline: the race on HLA-A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Quell TherapeuticsQEL-001
CAR-Treg (chimeric antigen receptor-engineered regulatory T cell) targeting HLA-A2
HLA-A2Phase 1Rejection; Transplant, LiverSep 2040

Conditions

Rejection; Transplant, Liver (1)

Modalities

small molecule (1)

Companies

Quell Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.